Castellan Group Has $832,000 Stock Position in Halozyme Therapeutics, Inc. $HALO

Key Points

• Castellan Group significantly reduced its stake in Halozyme Therapeutics by 93.7% in the second quarter, now holding only 16,000 shares worth about $832,000.
• Institutional investors own 97.79% of Halozyme's stock, with various hedge funds adjusting their positions, including Bessemer Group Inc. increasing its stake by 62.9%.
• Analysts have mixed views on Halozyme, with a consensus rating of "Hold" and target prices ranging from $55.00 to $90.00, reflecting varying confidence in the stock's performance.

Castellan Group trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 93.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,000 shares of the biopharmaceutical company's stock after selling 238,477 shares during the quarter. Halozyme Therapeutics makes up 0.2% of Castellan Group's portfolio, making the stock its 25th biggest position. Castellan Group's holdings in Halozyme Therapeutics were worth $832,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Penserra Capital Management LLC acquired a new stake in Halozyme Therapeutics in the first quarter worth about $125,000. Bessemer Group Inc. grew its position in shares of Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 207 shares during the period. Redhawk Wealth Advisors Inc. grew its position in shares of Halozyme Therapeutics by 14.8% during the 2nd quarter. Redhawk Wealth Advisors Inc. now owns 37,419 shares of the biopharmaceutical company's stock worth $1,947,000 after buying an additional 4,827 shares during the period. Fifth Third Bancorp grew its position in shares of Halozyme Therapeutics by 29.4% during the 1st quarter. Fifth Third Bancorp now owns 10,017 shares of the biopharmaceutical company's stock worth $639,000 after buying an additional 2,276 shares during the period. Finally, GAMMA Investing LLC grew its position in shares of Halozyme Therapeutics by 199.0% during the 1st quarter. GAMMA Investing LLC now owns 2,802 shares of the biopharmaceutical company's stock worth $179,000 after buying an additional 1,865 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on HALO. HC Wainwright boosted their target price on Halozyme Therapeutics from $85.00 to $90.00 and gave the stock a "buy" rating in a research report on Thursday, October 2nd. Zacks Research lowered Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday. The Goldman Sachs Group began coverage on Halozyme Therapeutics in a research report on Thursday, July 10th. They set a "neutral" rating and a $55.00 target price for the company. JPMorgan Chase & Co. boosted their target price on Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a "neutral" rating in a research report on Thursday, August 7th. Finally, Wall Street Zen lowered Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 5th. Six equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $70.44.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $65.11 on Friday. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. The stock has a 50 day simple moving average of $70.98 and a 200 day simple moving average of $62.00. Halozyme Therapeutics, Inc. has a 52-week low of $42.01 and a 52-week high of $79.50. The firm has a market capitalization of $7.62 billion, a PE ratio of 14.90, a P/E/G ratio of 0.35 and a beta of 1.16.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating the consensus estimate of $1.23 by $0.31. The firm had revenue of $325.72 million for the quarter, compared to analysts' expectations of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The business's quarterly revenue was up 40.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 2,000 shares of the business's stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $75.24, for a total value of $150,480.00. Following the sale, the director owned 44,952 shares in the company, valued at approximately $3,382,188.48. The trade was a 4.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Nicole Labrosse sold 2,227 shares of the business's stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $77.95, for a total value of $173,594.65. Following the completion of the sale, the chief financial officer owned 22,079 shares in the company, valued at $1,721,058.05. The trade was a 9.16% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 108,227 shares of company stock worth $7,779,595. Corporate insiders own 2.40% of the company's stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.